Searched for
EMPAGLIFLOZIN
As Empagliflozin goes off patent, 71 copies of the key diabetes drug roll out in a monthFollowing the expiration of Empagliflozin's patent, the Indian pharmaceutical market has seen a surge, with 71 new brands and 17 companies ...09 Apr, 2025, 12.51 AM IST- New affordable diabetes drug Empagliflozin launched in IndiaSeveral domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly reduced prices follo...12 Mar, 2025, 04.58 PM IST
- Indian pharma cos to launch cheaper diabetes medicine at 90% lower price soonDomestic drug companies in India are preparing to launch affordable generics of the diabetes drug Empagliflozin after the expiry of Boehrin...10 Mar, 2025, 04.05 PM IST
- Boehringer's Jardiance now gets CDSCO nod for chronic kidney diseaseThe Central Drugs Standard Control Organisation of India has approved Jardiance, a 10mg dosage form of empagliflozin, for the treatment of ...14 Feb, 2024, 10.39 PM IST
- Torrent Pharmaceuticals partner with Boehringer Ingelheim to co-market diabetes, cardiovascular medicinesBoth companies entered into partnership for the sales and co-marketing of Empagliflozin and its combinations including Cospiaq (Empaglifloz...14 Dec, 2022, 05.17 PM IST
- Boehringer Ingelheim obtains interim injunction against four Indian drug cos from selling its diabetes drugBI said the injunctions restrain the domestic pharma companies from infringing the patent of Linagliptin by advertising, launching, making,...07 Jun, 2022, 08.51 PM IST
- Boehringer Ingelheim gets CDSCO nod for Jardiance to treat for new heart failure indicationJardiance is the top selling drug of BI in India, used in treatment of type-2 diabetes and for the treatment of heart failure with reduced ...19 May, 2022, 10.46 PM IST
- Himachal Pradesh high court restrains DRL from selling BI's diabetic drug JardianceThe drugmaker said it is reviewing legal options including filing an appeal against the court order. Dr Reddy's has launched copies of Jard...31 Mar, 2022, 09.44 PM IST
- Boehringer Ingelheim gets interim injunction against Dr. Reddy’s Labs, MSN Labs against copies of anti-diabetes drugIn a statement to ET, BI confirmed it has obtained separate orders granting ad-interim injunction that restrains the two domestic pharmaceu...26 Oct, 2021, 03.44 PM IST
- MSN Labs launches patented diabetes pill Jardiance after DRL, heats up potential legal battleEarlier, ET reported that Dr Reddy's Labs has launched copies of Jardiance. It has a valid patent in India until 2025.18 Oct, 2021, 07.50 PM IST
- Dr Reddy's Labs launches copy of BI drug; move may lead to legal battleUnder its brand Vicra, Dr. Reddy's is expected to sell the drug in India at less than a third of the price charged by Boehringer Ingelheim....18 Oct, 2021, 10.40 AM IST
- Lupin gets USFDA nod for generic diabetes drugThe company has received tentative approval for the product in multiple strengths from the United States Food and Drug Administration (USFD...07 Jan, 2021, 04.53 PM IST
- Alembic Pharmaceuticals gets USFDA's tentative approval for type 2 diabetes drugThe tentatively approved abbreviated new drug application (ANDA) is therapeutically equivalent to the reference listed drug product Glyxamb...27 Aug, 2020, 12.00 PM IST
- Alembic Pharma gets tentative nod from USFDA for type-2 diabetes management drugAlembic Pharma said it is currently in litigation with Boehringer Ingelheim in District Court of Delaware and launch of the product will de...20 Jul, 2020, 11.59 AM IST
- Cadila Healthcare gains 2% on USFDA nod for Empagliflozin tabletsThe drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.13 Apr, 2020, 03.44 PM IST
- Zydus Cadila gets USFDA nod to market generic type 2 diabetes drugThe company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Empagliflozin tablets, in...10 Apr, 2020, 04.33 PM IST
- Boehringer Ingelheim India and Lupin enter agreement to market diabetes drugIMS values the Indian diabetes market is at Rs9,003 crore and has recorded it as growing at 19.5%, according to a release by Lupin.13 Oct, 2016, 07.53 PM IST
Load More
